The results of a number of studies have demonstrated the promise of adding intrahepatic arterial selective internal radiotherapy (SIRT) to chemotherapy for patients with liver metastases from colorectal cancer; however, the frequent progression of extrahepatic metastases observed in patients treated with SIRT in the SIRFLOX trial call the potential overall benefit of this approach into question.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
van Hazel, G. A. et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J. Clin. Oncol. 34, 1723–1731 (2016).
Argyriou, A. A. et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann. Oncol. 23, 3116–3122 (2012).
Dutton, S. J. et al. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional selective internal radiation therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer 14, 497 (2014).
Kennedy, A. et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int. J. Radiat. Oncol. Biol. Phys. 68, 13–23 (2007).
Van Hazel, G. et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J. Surg. Oncol. 88, 78–85 (2004).
Hendlisz, A. et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J. Clin. Oncol. 28, 3687–3694 (2010).
Gray, B. et al. Randomised trial of SIR-Spheres plus chemotherapy versus chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann. Oncol. 12, 1711–1720 (2001).
Sharma, R. A. et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J. Clin. Oncol. 25, 1099–1106 (2007).
Fakih, M. G. Metastatic colorectal cancer: current state and future directions. J. Clin. Oncol. 33, 1809–1824 (2015).
Kjellstrom, J., Kjellen, E. & Johnsson, A. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol. 44, 687–693 (2005).
Acknowledgements
The authors would like to thank Donna Pringle for her assistance with English-language editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.T. has served on advisory boards for Amgen, Bayer, Boehringer Ingelheim, Celgene, Chugai, Lilly, MSD, Merck Serono, Novartis, Roche, Sanofi, Symphogen, Taiho, and Takeda. R.S. has served as a speaker or on advisory boards for Amgen, Lilly, Merck Serono, Novartis, Roche, Sanofi, and Taiho.
Rights and permissions
About this article
Cite this article
Tabernero, J., Salazar, R. Light and shade of intrahepatic arterial radiotherapy in mCRC. Nat Rev Clin Oncol 13, 467–468 (2016). https://doi.org/10.1038/nrclinonc.2016.92
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.92
